Annual EBIT
-$580.11 M
-$391.94 M-208.30%
September 30, 2024
Summary
- As of February 7, 2025, ARWR annual earnings before interest & taxes is -$580.11 million, with the most recent change of -$391.94 million (-208.30%) on September 30, 2024.
- During the last 3 years, ARWR annual EBIT has fallen by -$439.26 million (-311.87%).
- ARWR annual EBIT is now -1048.03% below its all-time high of $61.19 million, reached on September 30, 2019.
Performance
ARWR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$158.15 M
+$10.73 M+6.35%
September 30, 2024
Summary
- As of February 7, 2025, ARWR quarterly earnings before interest & taxes is -$158.15 million, with the most recent change of +$10.73 million (+6.35%) on September 30, 2024.
- Over the past year, ARWR quarterly EBIT has dropped by -$38.40 million (-32.07%).
- ARWR quarterly EBIT is now -399.91% below its all-time high of $52.73 million, reached on March 31, 2023.
Performance
ARWR Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$580.11 M
-$54.42 M-10.35%
September 30, 2024
Summary
- As of February 7, 2025, ARWR TTM earnings before interest & taxes is -$580.11 million, with the most recent change of -$54.42 million (-10.35%) on September 30, 2024.
- Over the past year, ARWR TTM EBIT has dropped by -$125.08 million (-27.49%).
- ARWR TTM EBIT is now -1048.03% below its all-time high of $61.19 million, reached on September 30, 2019.
Performance
ARWR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ARWR EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -208.3% | -32.1% | -27.5% |
| 3 y3 years | -311.9% | -179.0% | -311.9% |
| 5 y5 years | -1048.0% | -179.0% | -311.9% |
ARWR EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -311.9% | at low | -399.9% | +6.3% | -439.6% | at low |
| 5 y | 5-year | -1048.0% | at low | -399.9% | +6.3% | -1378.0% | at low |
| alltime | all time | -1048.0% | at low | -399.9% | +6.3% | -1048.0% | at low |
Arrowhead Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | -$580.11 M(+208.3%) | -$158.15 M(-6.4%) | -$580.11 M(+10.4%) |
| Jun 2024 | - | -$168.88 M(+41.0%) | -$525.68 M(+15.5%) |
| Mar 2024 | - | -$119.75 M(-10.2%) | -$455.03 M(+61.0%) |
| Dec 2023 | - | -$133.32 M(+28.5%) | -$282.54 M(+50.2%) |
| Sep 2023 | -$188.16 M(+8.9%) | -$103.73 M(+5.6%) | -$188.16 M(+12.9%) |
| Jun 2023 | - | -$98.22 M(-286.3%) | -$166.59 M(+18.6%) |
| Mar 2023 | - | $52.73 M(-235.4%) | -$140.41 M(-5.6%) |
| Dec 2022 | - | -$38.95 M(-52.6%) | -$148.78 M(-14.1%) |
| Sep 2022 | -$172.71 M(+22.6%) | -$82.16 M(+14.0%) | -$173.16 M(+17.2%) |
| Jun 2022 | - | -$72.05 M(-262.4%) | -$147.69 M(+37.4%) |
| Mar 2022 | - | $44.37 M(-170.1%) | -$107.52 M(-40.3%) |
| Dec 2021 | - | -$63.32 M(+11.7%) | -$180.11 M(+27.9%) |
| Sep 2021 | -$140.85 M(+51.2%) | -$56.69 M(+77.9%) | -$140.85 M(+4.9%) |
| Jun 2021 | - | -$31.87 M(+12.9%) | -$134.27 M(+13.5%) |
| Mar 2021 | - | -$28.23 M(+17.4%) | -$118.35 M(+5.3%) |
| Dec 2020 | - | -$24.05 M(-52.0%) | -$112.36 M(+20.6%) |
| Sep 2020 | -$93.16 M(-252.2%) | -$50.12 M(+214.3%) | -$93.16 M(+178.9%) |
| Jun 2020 | - | -$15.95 M(-28.3%) | -$33.40 M(-3027.1%) |
| Mar 2020 | - | -$22.24 M(+358.3%) | $1.14 M(-97.5%) |
| Dec 2019 | - | -$4.85 M(-150.4%) | $45.39 M(-25.8%) |
| Sep 2019 | $61.19 M(-209.4%) | $9.64 M(-48.2%) | $61.19 M(+51.5%) |
| Jun 2019 | - | $18.60 M(-15.5%) | $40.38 M(+588.2%) |
| Mar 2019 | - | $22.01 M(+101.1%) | $5.87 M(-118.8%) |
| Dec 2018 | - | $10.95 M(-198.0%) | -$31.18 M(-44.3%) |
| Sep 2018 | -$55.94 M(+51.2%) | -$11.17 M(-29.8%) | -$55.94 M(+1.7%) |
| Jun 2018 | - | -$15.92 M(+5.9%) | -$55.02 M(+22.8%) |
| Mar 2018 | - | -$15.03 M(+8.8%) | -$44.81 M(+24.8%) |
| Dec 2017 | - | -$13.81 M(+34.8%) | -$35.91 M(-2.9%) |
| Sep 2017 | -$37.00 M(-53.6%) | -$10.25 M(+79.4%) | -$37.00 M(-20.4%) |
| Jun 2017 | - | -$5.71 M(-6.8%) | -$46.49 M(-22.7%) |
| Mar 2017 | - | -$6.13 M(-58.9%) | -$60.12 M(-20.1%) |
| Dec 2016 | - | -$14.90 M(-24.5%) | -$75.25 M(-5.6%) |
| Sep 2016 | -$79.69 M(-17.0%) | -$19.74 M(+2.1%) | -$79.69 M(-6.4%) |
| Jun 2016 | - | -$19.34 M(-9.0%) | -$85.18 M(+4.1%) |
| Mar 2016 | - | -$21.26 M(+9.9%) | -$81.83 M(-9.3%) |
| Dec 2015 | - | -$19.34 M(-23.3%) | -$90.20 M(-6.0%) |
| Sep 2015 | -$95.97 M(+87.8%) | -$25.23 M(+57.7%) | -$95.97 M(+5.6%) |
| Jun 2015 | - | -$15.99 M(-46.0%) | -$90.92 M(+3.8%) |
| Mar 2015 | - | -$29.63 M(+18.0%) | -$87.63 M(+26.6%) |
| Dec 2014 | - | -$25.12 M(+24.4%) | -$69.21 M(+35.4%) |
| Sep 2014 | -$51.10 M(+119.5%) | -$20.18 M(+58.9%) | -$51.10 M(+31.3%) |
| Jun 2014 | - | -$12.70 M(+13.3%) | -$38.92 M(+24.3%) |
| Mar 2014 | - | -$11.21 M(+60.0%) | -$31.30 M(+22.8%) |
| Dec 2013 | - | -$7.01 M(-12.4%) | -$25.48 M(+9.4%) |
| Sep 2013 | -$23.28 M(+10.4%) | -$8.00 M(+57.4%) | -$23.28 M(+12.7%) |
| Jun 2013 | - | -$5.08 M(-5.7%) | -$20.66 M(-7.7%) |
| Mar 2013 | - | -$5.39 M(+12.1%) | -$22.38 M(+2.4%) |
| Dec 2012 | - | -$4.81 M(-10.6%) | -$21.86 M(+3.7%) |
| Sep 2012 | -$21.09 M | -$5.38 M(-20.9%) | -$21.09 M(+13.2%) |
| Jun 2012 | - | -$6.80 M(+39.7%) | -$18.62 M(+37.0%) |
| Mar 2012 | - | -$4.87 M(+20.5%) | -$13.59 M(+29.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | -$4.04 M(+38.7%) | -$10.53 M(+7.2%) |
| Sep 2011 | -$9.83 M(+68.5%) | -$2.91 M(+64.5%) | -$9.83 M(+13.0%) |
| Jun 2011 | - | -$1.77 M(-2.3%) | -$8.70 M(+4.5%) |
| Mar 2011 | - | -$1.81 M(-45.7%) | -$8.32 M(+112.5%) |
| Dec 2010 | - | -$3.34 M(+86.9%) | -$3.92 M(+42.9%) |
| Sep 2010 | -$5.83 M(-70.2%) | -$1.79 M(+28.3%) | -$2.74 M(-38.3%) |
| Jun 2010 | - | -$1.39 M(-153.6%) | -$4.44 M(-17.1%) |
| Mar 2010 | - | $2.60 M(-220.1%) | -$5.35 M(-59.3%) |
| Dec 2009 | - | -$2.16 M(-38.0%) | -$13.14 M(-32.8%) |
| Sep 2009 | -$19.56 M(-44.1%) | -$3.48 M(+51.2%) | -$19.56 M(-29.2%) |
| Jun 2009 | - | -$2.30 M(-55.6%) | -$27.63 M(-21.6%) |
| Mar 2009 | - | -$5.19 M(-39.4%) | -$35.23 M(-5.1%) |
| Dec 2008 | - | -$8.58 M(-25.8%) | -$37.10 M(+4.8%) |
| Sep 2008 | -$35.00 M(-7.8%) | -$11.56 M(+16.8%) | -$35.41 M(-0.2%) |
| Jun 2008 | - | -$9.90 M(+39.9%) | -$35.50 M(-9.0%) |
| Mar 2008 | - | -$7.07 M(+2.7%) | -$39.00 M(-3.4%) |
| Dec 2007 | - | -$6.89 M(-40.9%) | -$40.36 M(+6.4%) |
| Sep 2007 | -$37.95 M(+85.3%) | -$11.64 M(-13.1%) | -$37.95 M(+18.0%) |
| Jun 2007 | - | -$13.40 M(+58.8%) | -$32.16 M(+38.1%) |
| Mar 2007 | - | -$8.44 M(+88.6%) | -$23.29 M(+12.0%) |
| Dec 2006 | - | -$4.47 M(-23.6%) | -$20.78 M(+1.8%) |
| Sep 2006 | -$20.48 M(+113.5%) | -$5.85 M(+29.4%) | -$20.42 M(+13.3%) |
| Jun 2006 | - | -$4.52 M(-23.8%) | -$18.02 M(+10.5%) |
| Mar 2006 | - | -$5.93 M(+44.3%) | -$16.30 M(+35.4%) |
| Dec 2005 | - | -$4.11 M(+19.1%) | -$12.04 M(+25.4%) |
| Sep 2005 | -$9.59 M(+256.5%) | -$3.45 M(+23.1%) | -$9.60 M(+26.9%) |
| Jun 2005 | - | -$2.81 M(+68.2%) | -$7.57 M(+41.2%) |
| Mar 2005 | - | -$1.67 M(-0.6%) | -$5.36 M(+26.9%) |
| Dec 2004 | - | -$1.68 M(+18.1%) | -$4.23 M(+57.1%) |
| Sep 2004 | -$2.69 M(+2750.4%) | -$1.42 M(+138.3%) | -$2.69 M(+108.9%) |
| Jun 2004 | - | -$596.00 K(+12.1%) | -$1.29 M(+82.2%) |
| Mar 2004 | - | -$531.50 K(+273.0%) | -$706.70 K(+245.2%) |
| Dec 2003 | - | -$142.50 K(+709.7%) | -$204.70 K(+116.6%) |
| Sep 2003 | -$94.40 K(-93.3%) | -$17.60 K(+16.6%) | -$94.50 K(-93.2%) |
| Jun 2003 | - | -$15.10 K(-48.8%) | -$1.40 M(-2.4%) |
| Mar 2003 | - | -$29.50 K(-8.7%) | -$1.43 M(+0.5%) |
| Dec 2002 | - | -$32.30 K(-97.6%) | -$1.42 M(+0.5%) |
| Sep 2002 | -$1.42 M(+1232.3%) | -$1.32 M(+2597.8%) | -$1.42 M(+1016.0%) |
| Jun 2002 | - | -$48.90 K(+118.3%) | -$126.90 K(+35.7%) |
| Mar 2002 | - | -$22.40 K(-12.8%) | -$93.50 K(-3.2%) |
| Dec 2001 | - | -$25.70 K(-14.0%) | -$96.60 K(-9.1%) |
| Sep 2001 | -$106.30 K(-2.7%) | -$29.90 K(+92.9%) | -$106.30 K(+2.1%) |
| Jun 2001 | - | -$15.50 K(-39.2%) | -$104.10 K(-6.9%) |
| Mar 2001 | - | -$25.50 K(-28.0%) | -$111.80 K(0.0%) |
| Dec 2000 | - | -$35.40 K(+27.8%) | -$111.80 K(+2.3%) |
| Sep 2000 | -$109.20 K(+94.3%) | -$27.70 K(+19.4%) | -$109.30 K(+33.9%) |
| Jun 2000 | - | -$23.20 K(-9.0%) | -$81.60 K(+39.7%) |
| Mar 2000 | - | -$25.50 K(-22.5%) | -$58.40 K(+77.5%) |
| Dec 1999 | - | -$32.90 K | -$32.90 K |
| Sep 1999 | -$56.20 K(+131.3%) | - | - |
| Sep 1998 | -$24.30 K(-84.7%) | - | - |
| Sep 1997 | -$158.60 K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual EBIT year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly EBIT year-on-year change?
- What is Arrowhead Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM EBIT year-on-year change?
What is Arrowhead Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ARWR is -$580.11 M
What is the all time high annual EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual earnings before interest & taxes is $61.19 M
What is Arrowhead Pharmaceuticals annual EBIT year-on-year change?
Over the past year, ARWR annual earnings before interest & taxes has changed by -$391.94 M (-208.30%)
What is Arrowhead Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ARWR is -$158.15 M
What is the all time high quarterly EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly earnings before interest & taxes is $52.73 M
What is Arrowhead Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, ARWR quarterly earnings before interest & taxes has changed by -$38.40 M (-32.07%)
What is Arrowhead Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ARWR is -$580.11 M
What is the all time high TTM EBIT for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM earnings before interest & taxes is $61.19 M
What is Arrowhead Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, ARWR TTM earnings before interest & taxes has changed by -$125.08 M (-27.49%)